CytoDyn Inc. (CYDY)
USD 0.12
(-2.91%)
USD 0.12
(-2.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -18.02 Million USD | 55.37% |
| 2023 | -40.4 Million USD | 49.66% |
| 2022 | -192.54 Million USD | 13.67% |
| 2021 | -92.75 Million USD | -26.57% |
| 2020 | 2.03 Million USD | -33.39% |
| 2019 | -54.45 Million USD | -19.71% |
| 2018 | -45.56 Million USD | -70.67% |
| 2017 | -26.96 Million USD | -26.3% |
| 2016 | -20.81 Million USD | -10.34% |
| 2015 | -19.33 Million USD | -151.51% |
| 2014 | -7.68 Million USD | -3.94% |
| 2013 | -7.39 Million USD | 0.76% |
| 2012 | 2013.00 USD | -101.7% |
| 2011 | 2880.00 USD | -0.65% |
| 2010 | 2077.00 USD | -209.78% |
| 2009 | -1.52 Million USD | -6.49% |
| 2008 | -1.07 Million USD | 48.4% |
| 2007 | -2.15 Million USD | -119.88% |
| 2006 | -1.93 Million USD | -26.82% |
| 2005 | -773.51 Thousand USD | -116.52% |
| 2004 | -357.24 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.82 Million USD | 25.75% |
| 2024 FY | - USD | 55.37% |
| 2024 Q4 | -6.63 Million USD | -50.15% |
| 2024 Q1 | -7.88 Million USD | -35.3% |
| 2024 Q3 | -7.84 Million USD | -43.71% |
| 2023 Q1 | -10.56 Million USD | -65.24% |
| 2023 FY | - USD | 49.66% |
| 2023 Q3 | -9.81 Million USD | 59.23% |
| 2023 Q4 | -17.05 Million USD | -73.8% |
| 2023 Q2 | -24.06 Million USD | -127.68% |
| 2022 Q1 | -21.42 Million USD | 8.42% |
| 2022 FY | - USD | 13.67% |
| 2022 Q4 | -6.39 Million USD | 75.69% |
| 2022 Q3 | -26.31 Million USD | -0.75% |
| 2022 Q2 | -26.11 Million USD | -21.91% |
| 2021 Q4 | -23.39 Million USD | -15.54% |
| 2021 Q1 | -25.07 Million USD | 5.84% |
| 2021 Q2 | -24.24 Million USD | 3.33% |
| 2021 FY | - USD | -26.57% |
| 2021 Q3 | -20.24 Million USD | 16.48% |
| 2020 Q1 | -12.39 Million USD | 8.79% |
| 2020 Q3 | -21.13 Million USD | -59.02% |
| 2020 FY | - USD | -33.39% |
| 2020 Q4 | -26.63 Million USD | -26.04% |
| 2020 Q2 | -13.28 Million USD | -7.22% |
| 2019 Q2 | -15.54 Million USD | -15.92% |
| 2019 Q1 | -13.4 Million USD | -20.72% |
| 2019 Q3 | -12.52 Million USD | 19.43% |
| 2019 Q4 | -13.58 Million USD | -8.51% |
| 2019 FY | - USD | -19.71% |
| 2018 Q2 | -10.85 Million USD | -10.41% |
| 2018 FY | - USD | -70.67% |
| 2018 Q1 | -9.83 Million USD | -27.55% |
| 2018 Q3 | -14.2 Million USD | -30.87% |
| 2018 Q4 | -11.1 Million USD | 21.81% |
| 2017 FY | - USD | -26.3% |
| 2017 Q2 | -6.05 Million USD | -15.13% |
| 2017 Q3 | -7.92 Million USD | -30.78% |
| 2017 Q4 | -7.7 Million USD | 2.72% |
| 2017 Q1 | -5.26 Million USD | 17.86% |
| 2016 Q1 | -6.91 Million USD | 33.3% |
| 2016 FY | - USD | -10.34% |
| 2016 Q2 | -3.16 Million USD | 54.24% |
| 2016 Q4 | -6.4 Million USD | -29.24% |
| 2016 Q3 | -4.95 Million USD | -56.59% |
| 2015 Q4 | -10.37 Million USD | -223.89% |
| 2015 Q1 | -2.86 Million USD | -15.86% |
| 2015 Q3 | -3.2 Million USD | -10.37% |
| 2015 FY | - USD | -151.51% |
| 2015 Q2 | -2.9 Million USD | -1.31% |
| 2014 Q1 | -924.65 Thousand USD | 45.48% |
| 2014 Q4 | -2.47 Million USD | 8.13% |
| 2014 Q3 | -2.69 Million USD | -67.95% |
| 2014 FY | - USD | -3.94% |
| 2014 Q2 | -1.6 Million USD | -73.24% |
| 2013 Q4 | -1.69 Million USD | -30.8% |
| 2013 FY | - USD | 0.76% |
| 2013 Q3 | -1.29 Million USD | 21.09% |
| 2013 Q2 | -1.64 Million USD | 41.57% |
| 2013 Q1 | -2.81 Million USD | 17.05% |
| 2012 Q1 | -1.15 Million USD | -5.28% |
| 2012 FY | - USD | -101.7% |
| 2012 Q4 | -3.38 Million USD | -139.65% |
| 2012 Q3 | -1.41 Million USD | 5.15% |
| 2012 Q2 | -1.49 Million USD | -28.82% |
| 2011 FY | - USD | -0.65% |
| 2011 Q2 | -1.05 Million USD | -78.51% |
| 2011 Q3 | -1.06 Million USD | -1.52% |
| 2011 Q4 | -1.09 Million USD | -3.01% |
| 2011 Q1 | -589.11 Thousand USD | 70.48% |
| 2010 Q4 | -1.99 Million USD | -179.95% |
| 2010 Q1 | -274.95 Thousand USD | -365.58% |
| 2010 Q2 | -688.06 Thousand USD | -150.25% |
| 2010 Q3 | -712.82 Thousand USD | -3.6% |
| 2010 FY | - USD | -209.78% |
| 2009 FY | - USD | -6.49% |
| 2009 Q1 | -552.05 Thousand USD | -13.05% |
| 2009 Q3 | -269.78 Thousand USD | 57.95% |
| 2009 Q4 | -59.05 Thousand USD | 78.11% |
| 2009 Q2 | -641.64 Thousand USD | -16.23% |
| 2008 Q2 | -247.07 Thousand USD | -10.39% |
| 2008 Q3 | -153.74 Thousand USD | 37.77% |
| 2008 Q4 | -488.31 Thousand USD | -217.61% |
| 2008 FY | - USD | 48.4% |
| 2008 Q1 | -223.81 Thousand USD | 53.55% |
| 2007 Q4 | -481.84 Thousand USD | 11.34% |
| 2007 FY | - USD | -119.88% |
| 2007 Q2 | -429.43 Thousand USD | 22.09% |
| 2007 Q1 | -551.17 Thousand USD | 28.77% |
| 2007 Q3 | -543.47 Thousand USD | -26.56% |
| 2006 FY | - USD | -26.82% |
| 2006 Q3 | -254.48 Thousand USD | -208.01% |
| 2006 Q2 | -82.62 Thousand USD | -23.21% |
| 2006 Q1 | -67.05 Thousand USD | 14.53% |
| 2006 Q4 | -773.74 Thousand USD | -204.04% |
| 2005 Q2 | -122.86 Thousand USD | -2.04% |
| 2005 Q1 | -120.4 Thousand USD | 28.55% |
| 2005 FY | - USD | -116.52% |
| 2005 Q3 | -451.77 Thousand USD | -267.69% |
| 2005 Q4 | -78.45 Thousand USD | 82.63% |
| 2004 Q1 | -1828.00 USD | 0.0% |
| 2004 Q2 | -58.12 Thousand USD | -3079.81% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | -128.99 Thousand USD | -121.92% |
| 2004 Q4 | -168.52 Thousand USD | -30.64% |
| 2003 Q1 | -3098.00 USD | 0.0% |
| 2003 Q2 | -2118.00 USD | 31.63% |
| 2003 Q3 | -1584.00 USD | 25.21% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 74.62% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -204.086% |
| SQZ Biotechnologies Company | -64.14 Million USD | 71.892% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -3.794% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 119.172% |
| Mesoblast Limited | -62.38 Million USD | 71.103% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1073.726% |
| Genus plc | 73.7 Million USD | 124.463% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -172.691% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -408.289% |
| Marizyme, Inc. | -34.28 Million USD | 47.409% |
| ContraFect Corporation | -64.99 Million USD | 72.263% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -105.529% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -298.326% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1186.125% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -581.768% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -675.835% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -3380.193% |
| Accustem Sciences Inc. | -3.74 Million USD | -381.233% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 62.616% |
| EV Biologics, Inc. | -1.26 Million USD | -1322.819% |
| Q BioMed Inc. | -617.62 Thousand USD | -2819.071% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 604.731% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2750.858% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -689.192% |
| Biomind Labs Inc. | -1.03 Million USD | -1642.692% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 282.535% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -151.757% |
| Skye Bioscience, Inc. | -13.54 Million USD | -33.079% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -1112.105% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -72016.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -364.148% |
| IMV Inc. | -35.52 Million USD | 49.248% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -13.606% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -620.594% |
| GB Sciences, Inc. | -1.41 Million USD | -1169.751% |
| Alpha Cognition Inc. | -9.7 Million USD | -85.759% |
| HST Global, Inc. | -5303.00 USD | -339877.371% |
| CSL Limited | 4.78 Billion USD | 100.376% |
| Halberd Corporation | -74.27 Thousand USD | -24172.002% |
| Enzolytics Inc. | -2.12 Million USD | -749.611% |
| Resverlogix Corp. | -11.74 Million USD | -53.543% |
| Affymax, Inc. | -14.29 Million USD | -26.121% |
| SYBLEU INC | -141.57 Thousand USD | -12634.953% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -488.603% |
| argenx SE | -216.02 Million USD | 91.654% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 67.421% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1581.43% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -1102.811% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 4858.951% |
| AVAX Technologies, Inc. | -6.11 Million USD | -194.946% |
| Zenith Capital Corp. | -8.6 Million USD | -109.493% |
| Genscript Biotech Corporation | -248.71 Million USD | 92.751% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -103390.041% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -636.942% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -10142.332% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 54.515% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -523.339% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1623.1% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 268229.09% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -930.229% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -838.565% |
| BioStem Technologies, Inc. | -7.55 Million USD | -138.679% |
| ONE Bio Corp. | 13.61 Million USD | 232.439% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -9855.933% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -776.471% |
| Agentix Corp. | -1.37 Million USD | -1214.301% |
| LadRx Corporation | 412.28 Thousand USD | 4472.967% |
| Cell Source, Inc. | -4.27 Million USD | -321.975% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -4809.578% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1329.846% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1824.224% |
| NovAccess Global Inc. | -1.03 Million USD | -1642.274% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 303.63% |
| Itoco Inc. | -1.86 Million USD | -864.636% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -4649.223% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1515.502% |
| Kadimastem Ltd | -2.62 Million USD | -586.981% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -7438.783% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -22713.145% |
| Mobile Lads Corp. | -2.24 Million USD | -704.45% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -147328.244% |
| Qrons Inc. | -40.08 Thousand USD | -44881.413% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -3612.13% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 3518.254% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1795.794% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1597.63% |
| International Stem Cell Corporation | 202 Thousand USD | 9025.248% |
| Bioxytran, Inc. | -3.82 Million USD | -371.945% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -34149.62% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -632.311% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 49.737% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -39964.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -558.473% |
| Neutra Corp. | -181.24 Thousand USD | -9847.199% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 10.566% |
| PureTech Health plc | -11.62 Million USD | -55.061% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 10.56% |
| IXICO plc | -707 Thousand USD | -2450.071% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -134.6% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 62.708% |
| CSL Limited | 4.73 Billion USD | 100.381% |
| Cellectis S.A. | -92.63 Million USD | 80.538% |